Logo image
Low-dose Craniospinal Irradiation and Ifosfamide, Cisplatin and Etoposide for Non-metastatic Embryonal Tumors in the Central Nervous System
期刊文章   同儕審查

Low-dose Craniospinal Irradiation and Ifosfamide, Cisplatin and Etoposide for Non-metastatic Embryonal Tumors in the Central Nervous System

Koichi Yasuda, Hiroshi Taguchi, Yutaka Sawamura, Jun Ikeda, Hidefumi Aoyama, Kenji Fujieda, Nobuaki Ishii, Masaaki Kashiwamura, Yoshinobu Iwasaki, Hiroki Shirato, …
Japanese journal of clinical oncology, 卷.38(7), 頁碼.486-492
01/07/2008
PMID: 18573848
Web of Science ID: WOS:000258139900006

摘要

chemotherapy late effect medulloblastoma primitive neuroectodermal tumor radiotherapy
Objective The current study was conducted to evaluate the effects of low-dose craniospinal irradiation (CSI) combined with chemotherapy on non-metastatic embryonal tumors in the central nervous system (CNS), including medulloblastoma and supra-tentorial primitive neuroectodermal tumors (ST-PNET). Methods All patients were treated according to the following protocol. After surgery, the patients ≤5 years old received 18 Gy and the patients >5 years old received 24 Gy CSI. The dose to the primary tumor bed was 39.6–54 Gy. Chemotherapy consisted of ifosfamide, cisplatin and etoposide (ICE chemotherapy). Results Sixteen patients aged 0.5–20.4 (median 6.1) years were enrolled and followed for 11–165 (median 112) months. Both 5-year actuarial overall survival (OAS) and progression-free survival (PFS) were 81% (95% confidence interval (CI): 62–100%) for the 16 patients. Both 5-year OAS and PFS were 82% (CI: 59–100%) for the patients with medulloblastoma and 80% (CI: 45–100%) for the patients with ST-PNET. Both 5-year OAS and PFS were 75% for the eight patients ≤5 years old and 88% for the eight patients >5 years old. Both 5-year OAS and PFS were 100% for six average-risk patients (3 years or older, total resection and posterior fossa) and 70% for 10 poor-risk patients (others). The median total intellectual quotient at the last follow-up was 85 (ranging from 48 to 103) in 12 patients who were followed for 3–145 (median 49) months. Eight patients received hormone replacement therapy. Conclusion Low-dose CSI and ICE chemotherapy may have a role as a treatment option for a subset of patients with non-metastatic embryonal tumors in the CNS.

檔案與連結 (1)

url
https://doi.org/10.1093/jjco/hyn049檢視
已出版(紀錄版本) 開放

相關連結

詳細資料

Logo image